secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001628280-24-036749
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx enters commercial supply agreement with Catalent for IBSRELA through 2028
--------------------------------------------------------------------------------

- Agreement covers tableting, testing, release and bulk packaging of IBSRELA (tenapanor HCl) at Catalent's Winchester, KY facility.
- Initial term through Dec 31, 2028, with automatic renewal for two-year terms thereafter.
- Minimum purchase commitment: minimum number of batches per contract year.
- Unit pricing adjusted annually starting Jan 1, 2025, based on producer price index.
- Either party can terminate for material breach after cure period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828024036749/0001628280-24-036749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828024036749/ardx-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-036749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer